A mixture of vascular eicosanoid urinary metabolites
Features
  • Each vial contains a mixture of standards packaged in amber ampules purged with argon
  • >1 ml provided at the concentration specified in the insert
  • Designed for direct snap and inject use in mass spectrometry applications
  • Ideally suited for method development and as a system suitability standard
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Vascular Eicosanoid Urinary Metabolite MaxSpec® LC-MS Mixture

Item No. 19668

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formulation
A solution in ethanol (1 μg/ml each compound)
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 ea

    $388

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    This mixture contains a collection of metabolites of the major vasoactive eicosanoids, prostaglandin I2 (PGI2; Item No. 18220) and thromboxane A2 (TXA2), as well as of several oxylipins postulated to regulate vasoconstriction. The mixture is supplied in an amber ampule in which the headspace has been purged with argon to prevent lipid oxidation. This product has been designed for direct use in LC-MS applications. The solution may be serially diluted for preparation of calibrators and QC standards and/or used directly as a system suitability standard or tuning standard. After opening, we recommend that the mixture be transferred immediately to a 1 ml glass screw cap vial, to prevent solvent evaporation, and stored at -20°C. The mixture should be discarded after multiple freeze/thaw cycles.

    Whereas PGI2 is a potent vasodilator and inhibitor of human platelet aggregation, TXA2 causes irreversible platelet aggregation and contraction of vascular and bronchial smooth muscle. Because both are rapidly metabolized, their urinary metabolites (11-dehydro TXB2 (Item No. 19500), 2,3-dinor TXB2 (Item No. 19050), 11-dehydro-2,3-dinor TXB2 (Item No. 19510), and 2,3-dinor-6-keto PGF1α (Item No. 15120), serve as useful markers for their synthesis.1,2,3,4,5,6 The diol metabolites of various epoxyeicosatrienoic acids (EETs) have been used to document the oxylipins involved in vasoconstriction and hypertension.7,8,9

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ishibashi, M., Watanabe, K., Ishizaki, F., et al. Dimethylisopropylsilyl ether derivative in gas chromatography/mass spectrometry of 2,3-dinor-11-dehydrothromboxane B2. Biol. Mass Spectrom. 20, 399-407 (1991).

    2. Lellouche, F., Fradin, A., FitzGerald, G., et al. Enzyme immunoassay measurement of the urinary metabolites of thromboxane A2 and prostacyclin. Prostaglandins 40(3), 297-310 (1990).

    3. Perneby, C., Granström, E., Beck, O., et al. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B2 in urine: Comparison with GC-MS. Thromb. Res. 96(6), 427-436 (1999).

    4. Ciabattoni, G., Pugliese, F., Davi, G., et al. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim. Biophys. Acta 992(1), 66-70 (1989).

    5. Fitzgerald, G.A., Lawson, J., Blair, I.A., et al. Analysis of urinary metabolites of thromboxane and prostacyclin by negative-ion chemical-ionization gas chromatography/mass spectrometry. Adv. Prostaglandin Thromboxane Leukot. Res. 15, 87-90 (1985).

    6. Krakoff, L.R., Vlachakis, N., Mendlowitz, M., et al. Differential effect of prostaglandin A1 in hypertensive patients with low, normal and high renin. Clin. Sci. Mol. Med. Suppl. 2, 311s-313s (1975).

    7. McGiff, J.C., and Quilley, J. 20-HETE and the kidney: Resolution of old problems and new beginnings. Am. J. Physiol. 277(3), R607-R623 (1999).

    8. Zhang, J.Y., Prakash, C., Yamashita, K., et al. Regiospecific and enantioselective metabolism of 8,9-epoxyeicosatrienoic acid by cyclooxygenase. Biochem. Biophys. Res. Commun. 183(1), 138-143 (1992).

    9. Fang, X., Kaduce, T.L., Weintraub, N.L., et al. Functional implications of a newly characterized pathway of 11,12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ. Res. 79(4), 784-793 (1996).